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1. Introduction
  One of the targets of the 'Millennium Development Goal' 
was to "achieve, by 2010, universal access to treatment 
for HIV/AIDS for all those who need it"[1]. In the year 2009, 
UNAIDS estimated 33.3 million people living with HIV 
worldwide, with more than 90% from the low and middle-
income countries, and the total deaths due to AIDS to be 
1.8 million[2]. Sub Saharan Africa is affected the most 
followed by South East Asia, thereby mostly affecting the 
poor socio-economies of the world[1]. Even though 5 million 
people in these low- and middle-income countries have 
access to antiretroviral therapy (ART), it represents only 
one third of the people who are in need of ART[3]. Access to 
antiretroviral treatment still remains a major barrier in these 
parts of the world. 
  The Indian National ART programme was launched in 
April, 2004 with a target of providing free ART to all people 
living with HIV (PLHIV) through ART centres and Link 
ART centres in the country, and in 2007, National AIDS 
Control Organisation (NACO) issued guidelines for scaling 
up ART in the country[4,5]. Although steady progress is 
being made towards achieving universal access to HIV 
prevention, treatment, care and support, yet ART initiation 
is often delayed. Significant proportions of patients still 
continue to be enrolled in the programme with advanced 
immunosuppression leading to higher mortality. Current 
antiretroviral therapeutic guidelines reflect the growing 
consensus that the early initiation of treatment for HIV 
is beneficial in terms of virological, immunological, and 
clinical outcome. The Indian National ART guideline 
was revised in 2009 raising the threshold of CD4 count 
to 250 cells/毺L for initiation of antiretroviral therapy 
irrespective of the clinical stage[5,6]. Early detection of 
asymptomatic HIV-1 infection increases the scope to 
control the transmission of infection and interventions in 
Objective: To assess early mortality and identify its predictors among the ART naive HIV-
infected patients initiating anti retroviral therapy (ART) available free of cost at the ART Centres. 
Methods: A retrospective cohort analysis of routinely collected programme data was done for 
assessing mortality of all ART naive adult patients who received first-line ART at a government 
tertiary care hospital in eastern India during 1st March 2009 and 28th February 2010. Bivariate 
and multiple regression analyses of the baseline demographic, clinical and laboratory records 
using SPSS 15.0 were done to identify independent predictors of mortality. Results: The mortality 
rate at one year was estimated to be 7.66 (95% CI 5.84-9.83) deaths/100 patient-years and more 
than 50% of the deaths occurred during first three months of ART initiation with a median time 
interval of 73 days. Tuberculosis was the major cause of death. ART naive patients with baseline 
serum albumin <3.5 mg/dL were eight (OR 7.9; 95% CI: 3.8-16.5) at risk of death than those with 
higher serum albumin levels and patients with CD4 count <100 cells/毺L were two times (OR 2.2; 
95% CI: 1.1-4.4) at risk of death compared to higher CD4 counts. Conclusions: Risk of mortality 
is increased when ART is initiated at advanced stages of immunosuppression denoted by low 
serum albumin levels and CD4 cell counts. This highlights the importance of early detection of 
HIV infection, early management of opportunistic infections including tuberculosis and timely 
initiation of the antiretroviral drugs in the resource-limited countries, now available free in the 
Indian national ART programme.
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the form of timely initiation of antiretroviral treatment to 
increase patients' life expectancy, with a faster resolution 
of opportunistic infections and a decreased risk of 
recurrence[6]. Delayed diagnosis and late entry, as indicated 
by low CD4 counts, into HIV care on the contrary results in 
early death among HIV-infected patients[6.7]. Malnutrition is 
another common hallmark of advanced HIV infection which 
plays a synergistic role in immune suppression initiated by 
HIV and is considered to be an independent risk factor for 
HIV disease progression[8]. The non pharmacological factors 
related to the PLHIV vary across the populations based 
on the socio-economic context[6]. Very few studies have 
examined the effects of pre-ART baseline characteristics 
on early mortality after initiation of ART among Indian 
population, and reports from the developed world are not 
necessarily applicable to such resource limited settings. 
Nevertheless, mortality has been found to be high in these 
parts of the world, particularly the initial months after 
starting ART[7-11]. A better knowledge of the pre ART factors 
contributing to this high mortality can help implement 
targeted interventions among the high risk patients, thereby 
helping to reduce excess mortality. The aim of this study was 
to assess mortality and to identify the predictors of mortality 
among the ART naive HIV-infected patients initiating ART 
from the ART Centres in Kolkata city. 
 
2.  Materials and methods
2.1. Programme description
  In the national ART programme, treatment is offered free 
of cost to all clinically eligible PLHIV. Patients diagnosed 
to be HIV positive at the integrated counselling and testing 
centre are further evaluated by a counsellor and a physician. 
They are subjected to baseline laboratory investigations 
including a CD4 test as per national treatment protocols[5]. 
If they are in WHO stage Ⅳ irrespective of CD4 cell count, 
WHO stage Ⅲ with CD4﹢ 350 cells/毺L, or have CD4﹢ 
250 cells/毺L regardless of clinical stage, then they are 
considered eligible for ART[5]. Any opportunistic infection 
is firstly treated to stabilise the patient and cotrimoxazole 
prophylaxis is started. After two weeks or when the patient 
is stabilised, whichever is later, and if they agree to adhere 
to treatment, then these ART naive patients are prescribed 
the first-line ART regimen consisting of either zidovudine 
or stavudine plus lamivudine plus a non-nucleoside reverse 
transcriptase inhibitor (nevirapine or efavirenz) depending 
upon the patient profile[5].
  For each patient registered for HIV care and treatment, 
a separate individual patient treatment record is filled in 
to record the sociodemographic characteristics, baseline 
clinical status, laboratory results and the prescribed ART 
regimen. These standardized patient cards are maintained at 
ART centres for tracking the progress of every patient. 
 
2.2. Study design
  A retrospective cohort analysis was done for records 
of all patients enrolled for first-line ART at the selected 
government run tertiary care hospital between 1st March 
2009 and 28th February 2010. All ART naive adult patients 
曒15 years of age excluding pregnant women, who were 
enrolled consecutively and registered to receive ART 
during this period were included in the study. Those lost to 
follow up or transferred out to other ART centres were also 
excluded.
2.3. Study setting
  Calcutta School of Tropical Medicine is a government run 
tertiary care hospital in Kolkata, the largest metropolis of 
eastern India, where an Antiretroviral Therapy Centre was 
started since March, 2005. Out of the four ART centres of 
the city, this ART Center is situated centrally and caters 
to maximum number of PLHIV in the state, maintaining 
good patient records and is also designated by NACO as the 
Centre of Excellence in HIV. 
2.4. Data abstraction 
  Data sources included the ART patient register, patient 
treatment cards and additional records, if any, kept at the 
ART centre. Uniform data abstraction was conducted using 
a structured format. Key baseline demographic, clinical 
and laboratory data including age, sex, education, marital 
status, monthly family income, history of smoking, history 
of alcohol, WHO clinical stage, weight, height, haemoglobin 
(Hb), serum albumin, CD4 count, active tuberculosis 
infection and particulars of ART regimen started were 
collected. No personal identification information was 
collected from the patient records during data abstraction. 
Body mass index (BMI) was calculated by standard 
procedure and patients were regarded as malnourished if 
BMI was <18.5 kg/m2. Each patient card was followed for 
one year from the date of start of ART to record any death 
reported within this period. The causes of death for all these 
cases were noted from in-patient records, by telephonic 
contact with their family members or relatives and with the 
help of home visits by outreach workers. 
2.5. Data entry, storage and statistical analysis
  All data abstracted were converted to an electronic 
format by entering them into Microsoft Office 2007 Excel 
spreadsheets and were cleaned for any error or outliers. This 
data was then imported into SPSS (version 15.0) for statistical 
analysis. Frequencies (with percentages) were calculated for 
all the variables. 
  The data of the dead and alive patients were statistically 
compared. Chi-square tests and Fisher's exact tests were 
used to examine any statistically significant associations. 
Odds ratios (with 95% confidence intervals, CI) were 
calculated. A P-value of less than 0.05 was considered to be 
statistically significant for all analyses. Multiple regression 
analysis was done including age, sex, current tuberculosis 
infection, WHO clinical stage, nutritional status (BMI kg/m2), 
serum albumin, Hb and CD4 count in the model using dead 
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status as the reference category. 
3. Results
  Of the 1 182 patients enrolled into HIV care during the 
study period, 759 ART naive adults initiating ART were 
included in the study. The median age of these PLHIV (66% 
male) was 35 years (range 15-75 years). The median BMI 
was18.22 kg/m2 (range 9.18-40.63 kg/m), median Hb was 
10.4 g/dL (range 4.4-16.6 g/dL); median serum albumin was 
3.9 mg/dL (range 1.2-9.2 mg/dL) and median CD4  count 
was 140 cells/毺L (range 3-735 cells/毺L). The baseline 
characteristics are given in Table 1.
  Among the study subjects, 56 patients died within one 
year of ART initiation and more than 50% of these deaths 
occurred during the first three months of ART initiation. 
The median time interval between ART initiation and time 
of death was 73 days. The mortality rate at one year was 
estimated to be 7.66 (95% CI 5.84-9.83) deaths/100 patient-
years. The causes of death are given in Table 2. Tuberculosis 
(extra-pulmonary, 39% and pulmonary, 9%) emerged out to 
be the major cause of death.
  The factors that emerged to be significant during bivariate 
analysis were BMI<18.5 kg/m2, Hb <9 g/dL, serum albumin 
<3.5 mg/dL, CD4 count <100 cells/毺L, presence of active 
tuberculosis and WHO clinical stages Ⅲ and Ⅳ as risk for 
mortality. The results of bivariate analysis are represented in 
Table 3. During multiple regression analysis, baseline serum 
albumin <3.5 mg/dL had eight times the risk (OR 7.9; 95% 
CI: 3.8-16.5) and CD4 count <100 cells/毺L had two times 
the risk (OR 2.2; 95% CI: 1.1-4.4) of mortality among these 
Indian PLHIV. The results of multiple regression analysis are 
given in Table 4. 
4. Discussion
  Mortality rate of this cohort was found to be 7.66 deaths/100 
patient-years at one year of starting ART with more than 
Table 1
Baseline characteristics [n(%)].
Variable Dead Alive Total  
Age ≤ 35years 28 (50.0) 397 (56.7) 425 (56.2)
> 35years 28 (50.0) 303 (43.3) 331 (43.8)
Gender Male 43 (76.8) 459 (65.6) 502 (66.4)
Female 13 (23.2) 241 (34.4) 254 (33.6)
Presence of spouse yes 39 (69.6) 486 (69.1) 525 (69.2)
no 17 (30.4) 217 (30.9) 234 (80.8)
Educational status illiterate 14 (25.0) 223 (31.8) 237 (31.3)
literate 42 (75.0) 478 (68.2) 520 (68.7)
Family income in Rupees ≤ 2000 35 (64.8) 359 (56.3) 394 (56.9)
>2000 19 (35.2) 279 (43.7) 298 (43.1)
History of smoking never smoked 26 (46.4) 352 (50.3) 378 (50.0)
ever smoked 30 (53.6) 348 (49.7) 378 (50.0)
History of alcohol never consumed 27 (48.2) 327 (46.8) 354 (46.9)
ever consumed 29 (51.8) 372 (53.2) 401 (53.1)
Active  tuberculosis present 27 (9.5) 258 (90.5) 285 (38.4)
absent 25 (5.5) 433 (94.5) 458 (61.6)
 WHO clinical stage Stages 栿 & 桇 24 (43.6) 196 (28.1) 220 (29.2)
Stage栺& 栻 31 (56.3) 502 (71.9) 533 (70.8)
Source: Primary survey, 2009-11 Kolkata. 
50% of these deaths occurring within three months of ART 
initiation. Studies have suggested that PLHIV initiating 
ART in the developing world have higher rates of mortality 
during the initial months of therapy, compared to those in 
developed countries[8,11-14]. Under similar limited-resource 
settings, a study from Senegal has reported higher mortality 
rate although studies from South Africa and Zambia have 
shown lower mortality rates at one year[7,10,15,16]. A study 
conducted in western India during the period when free 
ART roll out programme was not started in the country have 
reported mortality rate nearly double the rate observed in the 
present study from eastern India[17]. Provision of ART, free of 
cost, to these PLHIV through the current national programme 
could have been the major factor behind such lowering of 
mortality rate[11]. Early treatment deaths are due to advanced 
immunodeficient status at enrollment and independent of the 
responses of ART that defines the late deaths. Furthermore 
Table 2
The causes of death.
Cause of death n (%)
Extra -pulmonary tuberculosis 22 (39.3)
Pulmonary tuberculosis 5 (8.9)
Cryptococcal meningitis 5 (8.9)
Pneumocystis jiroveci pneumonia 3 (5.4)
Diarrhea 2 (3.6)
Septicemia 2 (3.6)
Toxoplasmosis 2 (3.6)
Encephalopathy 2 (3.6)
Nevirapine induced severe rash 1 (1.8)
Drug induced hepatitis 1 (1.8)
Cerebro-vascular accident 3 (5.4)
Acute myocardial infarction 2 (3.6)
Cause of death could not be ascertained 6 (10.7)
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Table 3
Predictors of mortality: results of bi-variate analyses. 
Variable Dead  [n (%)] OR (95% CI) of death P value
Nutritional status BMI <18.5 kg/m2 40 (12.3)   2.4 (1.3-4.4) 0.003
BMI >18.5 kg/m2 r 16 (5.5)
Hb level <9 g/dL 20 (11.8)   2.2 (1.2-4.1) 0.006
≥9 g/dLr 31 (5.6)
Serum albumin <3.5 mg/dL 45 (30.4) 11.2 (5.6-22.5) 0.000
≥3.5 mg/dL r 11 (3.8)
CD4 count <100 cells/毺L 36 (12.9)   3.5 (1.9-6.2) 0.000
≥100 cells/毺L r 19 (4.1)
Active tuberculosis present 27 (9.5)   1.8 (1.0-3.2) 0.037
absent r 25 (5.5)
WHO clinical stage Stages 栿 & 桇 24 (10.9)   1.9 (1.1-3.5) 0.015
Stage栺& 栻r 31 (5.8)
OR: Odds ratio; CI: Confidence interval; r: Reference category;  
Dependent variable: Death, other variable(s) considered and not found to be significant includes age, gender, presence of spouse, educational 
status, family income, history of smoking and alcohol consumption.
Table 4
Predictors of mortality: results of multiple regression analyses. 
Variables: Adjusted OR for death
95% CI for adjusted OR
Significance(P-value)
Lower Upper
Serum albumin <3.5 mg/dL 7. 9 3.8 16.5 0.000
≥3.5 mg/dL r
CD4 count <100 cells/毺L 2.2 1.1 4.4 0.029
≥100 cells/毺L r
OR: Odds ratio; CI: Confidence interval; r: Reference category;  Dependent variable: Death, other variable(s) considered in this model and not 
found to be significant includes the current tuberculosis infection, nutritional status (BMI<18.5 kg/m2), Hb <9 g/dL and WHO clinical stage 桇.
the most important cause of these deaths was found to be 
due to tuberculosis, both extra-pulmonary and pulmonary 
together, causing 48% of the total deaths in our study, almost 
equal to that reported by Ghate et al[17]. This could be 
attributed to the high prevalence of tuberculosis in India and 
its coexistence with HIV. Tuberculosis is still the commonest 
opportunistic infection among the PLHIV as reported from 
other parts of India[17-19].
  Serum albumin levels of the ART naive PLHIV prior to start 
of their ART was a strong predictor of mortality in our study. 
A serum albumin level <3.5 mg/dL carried eight times the 
risk for mortality compared to higher levels. A study from 
the US has shown that serum albumin level <3.5 mg/dL had 
3 times higher risk of death among HIV positive American 
women[18] HIV infection is known to be associated with 
systemic inflammation and elevations in the levels of pro-
inflammatory cytokines leading to vascular endothelial 
dysfunctions. Serum albumin has direct protective effect 
on this by the virtue of its vaso-dilating, anti-haemostatic 
and platelet-lowering properties coupled with its 
antioxidant and antiviral activities[19,20]. During advanced 
immunosuppressed stages there is widespread inflammation 
and HIV-1 disrupts the barrier function of the endothelium, 
resulting in increased transcapillary escape of albumin with 
dissemination of HIV-infected cells into tissue, thereby 
enhancing disease progression[21]. HIV infection also induces 
a hypermetabolic state in the host and HIV-related anorexia 
further depresses albumin synthesis creating a vicious cycle 
of malnutrition[18]. Diminished serum albumin levels, the 
marker of poor nutritional status induced by the stress of 
illness, appear long before any change in body weight or 
other clinical markers become evident[22]. Associated active 
tuberculosis also induces a lowering effect on serum albumin 
level[23]. Serum albumin remained as a powerful predictor 
of mortality not only in severely immunosuppressed states 
(CD4 cell count <100 cells/毺L) but even in patients not 
acutely ill with normal hepatic and renal functions as 
measured by levels of blood urea nitrogen, serum creatinine 
and transaminases[18]. A simple prognostic model based on 
albumin level could therefore be a useful tool for initial risk 
assessment in resource-limited settings. Future research 
to find out any role of albumin supplementation during 
initiation of ART in reducing mortality in the current setting 
can be undertaken. 
  Baseline CD4 cell count <100 cells/毺L was another strong 
predictor of mortality in our study. PLHIV initiating ART 
with plasma CD4 count <100 cells/毺L were two times at 
risk of death compared to higher CD4 cell counts. Studies 
from Africa have demonstrated CD4 count <50 cells/毺L as 
a strong predictor of mortality whereas earlier studies from 
India have reported CD4 count <200 cells/毺L to be a strong 
predictor[24-26]. Yet, a recent study from western India has 
demonstrated baseline CD4 cell count <100 cells/毺L as a 
risk of mortality[17]. Although low serum albumin levels and 
low CD4 cell count at baseline were independent risk of 
mortality in our study, it is important to note that diminished 
CD4 T cell function is associated with falling serum albumin 
levels and rising serum immunoglobulin levels reversing the 
albumin: globulin ratio in immune compromised persons. 
Studies have substantiated the fact that low CD4 cell count, a 
marker of advanced immunodeficiency, was associated with 
opportunistic infection thereby increasing the likelihood of 
death[17,24-27]. Early detection of HIV-infected individuals 
and timely initiation of ART could therefore prevent deaths 
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in the Indian setting.
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